 |
 Video: What is a Stock Split?
|
|
|
| Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultrarare genetic diseases. Their therapies and pipeline include biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Approved products are Crysvita for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii for mucopolysaccharidosis VII (MPSVII), Dojolvi for long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza for homozygous familial hypercholesterolemia (HoFH). Clinical candidates include DTX401 for glycogen storage disease type Ia, DTX301, and UX701. According to our RARE split history records, Ultragenyx Pharmaceutical has had 2 splits. | |
|
Ultragenyx Pharmaceutical (RARE) has 2 splits in our RARE split history database. The first split for RARE took place on September 06, 2000. This was a 3 for 2 split, meaning for each 2 shares of RARE owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. RARE's second split took place on September 03, 2003. This was a 3 for 2 split, meaning for each 2 shares of RARE owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.
When a company such as Ultragenyx Pharmaceutical splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the RARE split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ultragenyx Pharmaceutical shares, starting with a $10,000 purchase of RARE, presented on a split-history-adjusted basis factoring in the complete RARE split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/11/2014 |
|
| End date: |
12/09/2024 |
|
| Start price/share: |
$39.09 |
|
| End price/share: |
$49.32 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
26.17% |
|
| Average Annual Total Return: |
2.35% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$12,615.55 |
|
| Years: |
10.00 |
|
|
|
| Date |
Ratio |
| 09/06/2000 | 3 for 2 | | 09/03/2003 | 3 for 2 |
|
|
Free RARE Email Alerts:
